GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Research has led to the development of tailored treatment options for different cancers in different patients. Despite some treatments being able to provide remarkable responses, nearly all current treatments encounter the same issue: resistance. Here, we discuss our experiences with how breast cancers resist therapies. The focus of our discussion revolves around the cancer stem cell subpopulation and their mechanisms for resistance.

Cite

CITATION STYLE

APA

Nguyen, K., McConnell, E., Edwards, O., Collins-Burow, B. M., & Burow, M. E. (2022). GD2+ cancer stem cells in triple-negative breast cancer: mechanisms of resistance to breast cancer therapies. Cancer Drug Resistance, 5(3), 721–726. https://doi.org/10.20517/cdr.2022.30

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free